# Zai Lab

Source: https://onco.cc/companies/zai-lab/  
OnCo record `zai-lab` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zai Lab is the in-licensing pioneer that brings Western cancer drugs to China (niraparib, zanidatamab, repotrectinib, Tumour Treating Fields) and now exports its own bispecific and ADC assets.

## Summary

Founded by Samantha Du; built on Greater China rights to niraparib (Zejula), zanidatamab, repotrectinib, tislelizumab-adjacent assets, sulbactam-durlobactam and Optune, with a Shanghai commercial organisation of hundreds. Internal pipeline: ZL-1310 (DLL3 ADC), ZL-1503 and the LRRC15 ADC ZL-6201 from MediLink. A bridge company: it explains how Western drugs reach Chinese patients years earlier than they otherwise would.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: 再鼎医药
- Tags: china
- HQ: Shanghai / Cambridge, MA
- Type: biotech
- Website: https://www.zailaboratory.com/
- Ticker: ZLAB / 9688.HK

## Sources

- Official website: https://www.zailaboratory.com/

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Niraparib](https://onco.cc/drugs/niraparib/), [Optune / Optune Pax (TTFields)](https://onco.cc/drugs/optune/), [Repotrectinib](https://onco.cc/drugs/repotrectinib/), [Zanidatamab](https://onco.cc/drugs/zanidatamab/), [ZL-1310](https://onco.cc/drugs/zl-1310/)
- companies: [GSK](https://onco.cc/companies/gsk/), [Jazz Pharmaceuticals](https://onco.cc/companies/jazz/), [MediLink Therapeutics](https://onco.cc/companies/medilink/), [Novocure](https://onco.cc/companies/novocure/), [Zymeworks](https://onco.cc/companies/zymeworks/)
- trials: [A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther](https://onco.cc/trials/nct07796100/), [A Study of ZL-1310 in Participants With Selected Solid Tumors](https://onco.cc/trials/nct06885281/), [A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)](https://onco.cc/trials/dllevate/)
- people: [Samantha Du (Du Ying)](https://onco.cc/people/du-samantha/)

---
JSON: https://onco.cc/api/v1/entities/zai-lab.json